Eton Pharmaceuticals – DESMODA™: Enabling Brand Readiness for a Pediatric-Friendly Treatment in Central Diabetes Insipidus

Eton Pharmaceuticals partnered with Brandsymbol to develop a distinctive brand name for ET-600, a patented oral liquid formulation of desmopressin designed to treat central diabetes insipidus (CDI) in both pediatric and adult patients. CDI is a rare endocrine disorder in which the body cannot produce enough antidiuretic hormone, leading to excessive thirst and urination. Existing treatments, primarily tablets and nasal sprays, can present challenges for certain patients, particularly children. ET-600 was developed to address this unmet need by offering a stable, ready-to-use liquid formulation that enables precise and flexible dosing.

Brandsymbol collaborated closely with the Eton team through a strategy workshop and creative development process guided by our i4 Methodology. The naming strategy focused on communicating precision, safety, simplicity, and reassurance, qualities essential for a therapy used by pediatric patients, caregivers, and endocrinologists managing a lifelong condition. Creative exploration emphasized suggestive and descriptive naming approaches that would convey clinical credibility while remaining approachable and easy to pronounce.

The final name, DESMODA™, combines the recognizable root “DESM”, referencing the active ingredient desmopressin, with a soft, pronounceable ending that conveys comfort and balance. The result is a name that feels both clinically grounded and reassuring, aligning with the therapy’s goal of providing reliable symptom control and peace of mind for patients and caregivers.

DESMODA™ later received FDA approval as an oral solution for central diabetes insipidus, providing a convenient dosing option that improves treatment flexibility and accessibility, particularly for pediatric patients who may have difficulty
swallowing tablets or achieving consistent dosing with nasal sprays. Learn more about Eton Pharmaceuticals.

This launch represents an important advancement in CDI care and demonstrates how strategic brand development supports the successful introduction of innovative therapies. Explore our services.